23 May 2013
Keywords: Genzyme, Mozobil, Wales, UK, NICE
Article | 09 April 2010
US biotechnology firm Genzyme has welcomed the decision by the All Wales Medicines Strategy Group (AWMSG) to recommend its Mozobil ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 April 2010
8 April 2010
22 May 2013
© 2013 thepharmaletter.com